NFKB1 and systemic lupus erythematosus: This study proposed that PF inhibits LPS-induced cell activation by inhibiting the IRAK1-NF-κB pathway in MRL/lpr mouse macrophages, thereby showing potential as a treatment of SLE (Ji et al., 2018) and CLE by extension.